Supriya peshin

Reuniting with my mentor is a dream come true! An awe-inspiring moment with this dynamic GI oncologist 💕👑 Women empowering women. The art of mentorship , sponsership and allyship.. @WomeninOnc @ASCO @UAZCancer @UAZHemeOnc

Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72) - ORR: 76% - Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response - New SoC #lcsm #LungCancer #OncTwitter

@curecc @melinda_bachini 💚

Sixteen years ago, @melinda_bachini walked into the National Cancer Institute as “Patient 3737.”  "While not being called by my name may be impersonal, this number was a lifeline. It represented my place in a clinical trial—my last chance after standard treatments had failed." Sixteen years later, Melinda is enjoying life as a mother, wife, grandmother, patient advocate, and living proof of the life-changing power of clinical trials. 💚 Melinda's journey from Patient 3737 to survivor to advocate is a testament to what’s possible when patients and scientists work together. Patients aren’t just getting access to potentially effective treatments; they are leading the way in groundbreaking discoveries. Read more at: copingmag.com/from-patient-3….

Excited to host the 2026 Birmingham Cholangiocarcinoma Symposium on Feb 20 in Birmingham, AL. A day dedicated to advancing the science of #Cholangiocarcinoma — bringing together experts, researchers, patients & advocates to improve outcomes. Join us: curecca.org/birmingham2026

New Publication! A rare and fascinating presentation highlighting the clinical heterogeneity of Congenital Erythropoietic Porphyria. Grateful to my co-authors for the collaboration. mdpi.com/3732516 #mdpireports via @Reports_MDPI @supriyadocc

@realbowtiedoc @doctorC369 @RyanNipp @ASCO @cancerassassin1 @UGrewalMD @ipreeshagul @NiuSanford @ShaalanBeg @ShrutiPatelMD @ARosen380 @NarjustFlorezMD @marklewismd @AnaVManana @COlazagasti @Latinamd @lungoncdoc lol noice !!!

#TBT Wearing 7 pagers as a #MedStudent is such an odd #flex. @doctorC369 @RyanNipp @ASCO @cancerassassin1 @supriyadocc @UgrewalMD @ipreeshagul @NiuSanford @ShaalanBeg @ShrutiPatelMD @ARosen380 @NarjustFlorezMD @marklewismd @AnaVManana @COlazagasti @Latinamd @lungoncdoc @TimothyJBrownMD @rachnatshroff @OncBrothers @fumikochino @PallOncCoP @MazieTsangMD @DarcyBurbage @Chaosdyna @crisbergerot @GretchenMcnally @BbaharK @asfeen_ummul @veladconmigo @FionnualaCrowle @jillfeldman4 @IshwariaMD @SrinishantR @AjuVaniBabu @rabrazzak @TamrynGray @anhbl9

Good job @EhabTakrori ! Kudos to teamwork !! @shafiarahman_

Honored to present my poster at #ASCOGI 2026 (#GI26) on Serial ctDNA Dynamics in Metastatic and Locally Advanced PDAC Inspiring discussions and outstanding posters throughout the meeting. Grateful for the mentorship and support of @supriyadocc and @shafiarahman_

Here at #GI26? See you tonight at Advancements in Oncology! In Person, Date: Jan 9, 2026 ⏰ Time: 6:30-8:30 PM ✅ Register here: bit.ly/aiogi26 PancBiliary: @DrShubhamPant & @CentralParkWMD UpperGI: @DrR_DUNNE & @TimothyJBrownMD Colon & NET: @NVijayvergiaMD & @AnwaarSaeed3 #OncTwitter #MedTwitter #gism #AdvInOnc26 @OncUpdates

#GI26 This one stopped me in my tracks 🤯 We now have multiple reference points for single-agent IO in MSI-H mCRC. KEYNOTE-177 with pembrolizumab set the first-line bar. CheckMate 8HW with nivolumab showed very durable disease control. And now we have COMMIT. ASCO GI 2026, Abstract 14 COMMIT phase 3 in 1L dMMR/MSI-H mCRC FOLFOX + bev + atezolizumab vs atezolizumab alone PFS 30.0 vs 4.3 months, HR 0.44 ORR 80.6 vs 46 percent DCR at 12 months 62.9 vs 32.4 percent That disease control rate in the atezolizumab arm is abysmal for this biology. So what’s going on? 1. Is this finally closing the PD-1 vs PD-L1 debate in MSI-H colorectal cancer? 2. Is this a molecule issue, a trial design issue, or patient selection? COMMIT was amended post KEYNOTE-177 and ended up much smaller than planned, so the details matter. 3. What does this mean for ATOMIC? If PD-L1 monotherapy underperforms this badly in metastatic disease, the implications spill into earlier-stage strategies. This needs a very close look when the full dataset is presented. Something here does not add up. @OncoAlert @TheGutOncLab @TimothyJBrownMD you called this one 100%, looking forward to discussing with you and @UGrewalMD.

Advances in Targeted Therapy for NSCLC - @supriyadocc oncodaily.com/voices/supriya… #Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag

@HemOncFellows @AgrimaMianMD @The_heme_story @KalantriShreyas @ASH_hematology @Charbel_matar1 @DrSAHaddad @Noha_Soror @msalmanfaisal @cli4d_ @AndreaAnampaG Really looking forward to it @AgrimaMianMD ❤️

✍️Mark your calendar for our next upcoming space❗️ Navigating ASH: Tips, Strategy, and What to Expect‼️ Speakers: @AgrimaMianMD and @The_heme_story Host: @KalantriShreyas ⏰Monday, December 1st, 2025 📍X space at 6 pm EST

@RManochakian @DevikaDasMD

Publication Alert ‼️ Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions 🫁mdpi.com/3609900 #mdpiijms via @IJMS_MDPI @EhabTakrori @aditdharia @asfeen_ummul @oncodaily @IMG_Oncologists @SakshiSingal2

Publication Alert ‼️ Therapeutic Frontiers in Gastroesophageal Cancer: Contemporary Concepts in Management and Therapy mdpi.com/3606790 #mdpiijms via @IJMS_MDPI @EhabTakrori @IMG_Oncologists @oncodaily @GiOncNow @hemeoncfellow @SakshiSingal2

Publication Alert ‼️ Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion of Patients with Brain Metastases and Leptomeningeal Disease - Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-… @IvyLorena_Md @AnaVManana @oncodaily @ClinicalLung

@Rupayan_MD @aakonc Lucky you @Rupayan_MD congratulations

Proud mentee moments Learning the art of grant writing with Dr Khorana @aakonc has been such a privilege. The thought process, discipline, and vision behind every line remind me why mentorship matters. #MedTwitter #Oncology #asco

Interesting read !! 📕 Association Between Metabolic Syndrome and Risk of Laryngeal Cancer: A Systematic Review mdpi.com/3587094 #mdpicurroncol via @CurrentOncology @Faizanblone @lalithchow @SakshiSingal2 @oncodaily @IMG_Oncologists @hemeoncfellow @HemOncFellows

@Dr_R_Kurzrock @DrYujiUehara Interesting read . Thank you for sharing :)

Hot off the press. 🔥 pubmed.ncbi.nlm.nih.gov/41182434/Under… CD40 and immunity in cancer ⁦@DrYujiUehara⁩